<DOC>
	<DOCNO>NCT01040338</DOCNO>
	<brief_summary>A substantial body evidence implicate endogenous opioid system , mu opioid receptor ( MOR ) particular , reinforce effect drug abuse , include nicotine . A single nucleotide polymorphism ( SNP ) mu opioid receptor gene ( OPRM1 Asp40 ) associate ability quit smoking , well nicotine reward withdrawal symptom . However , precise mechanism SNP influence nicotine dependence remain unresolved . This positron emission tomography ( PET ) study examine whether OPRM1 SNP alters MOR bind response nicotine human smoker . Specifically , use [ 11 C ] carfentanil PET image assess effect intravenous ( IV ) nicotine versus saline ( within-subject ) MOR bind potential 24 chronic smoker genotyped prospectively stratify OPRM1 genotype .</brief_summary>
	<brief_title>Effects Nicotine Brain Opioid Receptors</brief_title>
	<detailed_description>The study use mixed factorial design one subject factor ( OPRM1 genotype_ : Asn40/Asn40 vs. Asn40/Asp40 Asp40/Asp40 ) one within-subject factor ( IV nicotine vs. IV saline ) examine genotype nicotine interaction MOR bind potential ( BP_ND ) assess via PET image [ 11 C ] carfentanil . Twenty-four smoker ( 12 male , 12 female ; 12 genotype group ) participate two 90 minute PET session follow overnight ( 14-hours ) abstinence nicotine . Genotype group match age sex . One week prior first PET session , adaptation session participant receive IV saline follow 30 minute later IV nicotine ( 1 mg/70 kg ) ensure tolerate procedure . In PET session , participant receive either IV nicotine ( 1 mg/70 kg ) saline ( within-subject , double blind , counterbalance ) . The primary outcome BP_ND ventral striatum anterior cingulate cortex ( ACC ) . Normally menstruate woman schedule session early follicular phase . Sessions separate 1 month participant reduce variability MOR binding due hormonal change females menstrual cycle . Participants complete subjective measure nicotine reward crave session .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>Nontreatment seek smoker European ancestry Between 18 50 year old Smoking least 10 cigarette per day least past 6 month Able provide inform consent Fluent , Englishspeaking Weight ≤ 300 lb . Current enrollment plan enroll smoke cessation program , use smoke cessation medication next 2 month Provide Carbon Monoxide read ≤10 ppm Medical screening . History substance abuse and/or currently receive treatment substance abuse ( e.g. , alcohol , opioids , cocaine , marijuana , stimulant ) Current alcohol consumption exceed 25 standard drinks/week Providing breath alcohol concentration ( BAC ) read &gt; 0.01 session . Women pregnant , planning pregnancy , lactate ; female subject shall undergo urine pregnancy test session Women childbearing age must agree write use approve method contraception History current diagnosis psychosis , major current depression bipolar disorder , ADHD , schizophrenia , Axis 1 disorder identify MINI Serious unstable disease within past 6 month ( e.g. , cancer [ except melanoma ] , heart disease , HIV ) History epilepsy seizure disorder History current diagnosis ( last 6months ) abnormal rhythm and/or tachycardia ( &gt; 100 beats/minute ) ; history current diagnosis COPD , cardiovascular disease ( stroke , angina , coronary heart disease ) , heart attack last 6 month , uncontrolled hypertension ( SBP &gt; 150 DBP &gt; 90 ) Any medical neurological condition might interfere distribution radiotracer determine study MD Current past use ( within past 12 month ) medication contain naltrexone MOR antagonist ( e.g. , Revia , Trexan ) Current use recent discontinuation ( within last 14days ) follow medication Any form smoking cessation medication ( Zyban , Wellbutrin , Wellbutrin SR , Chantix , NRT ) Recent ( within last 2 week ) plan use psychotropic medication ( antipsychotic , antidepressant ( tricyclic , SSRI , MAOI ) , antianxiety panic medication , stimulant ( e.g. , Provigil , Ritalin ) , opiatecontaining medication chronic pain Allergic response form opioids naloxone Participants shall instruct refrain use study prohibit drug ( note participant allow take prescription medicine exclusion list ) throughout participation study . Selfreported history head trauma prior seizure , brain ( CNS ) tumor Selfreported history claustrophobia ( contraindicate PET ) Inability complete baseline study procedure within four hour and/or correctly , determine principal investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>Smoking</keyword>
	<keyword>Tobacco</keyword>
	<keyword>Nicotine</keyword>
	<keyword>Dependence</keyword>
	<keyword>Genetics</keyword>
</DOC>